The insulin receptor substrate-1 (IRS-1) gene has been considered a candidate for insulin resistance, type 2 diabetes, and coronary artery disease. To investigate the relationship between the common Gly(972)Arg IRS-1 variant and the presence of cardiovascular risk factors, 153 glucose-tolerant, unrelated offspring of type 2 diabetic patients were studied. There were no differences between Arg(972) IRS-1 carriers and noncarriers in age, gender, body mass index, waist/hip ratio, body composition, fasting glucose and insulin levels, and glucose or insulin levels during the oral glucose tolerance test. Insulin sensitivity, assessed by hyperinsulinemic-euglycemic clamp, was significantly reduced in carriers of Arg(972) IRS-1 (P < 0.03). Carriers of Arg(972) IRS-1 displayed many features of the insulin resistance syndrome, including higher values for serum triglycerides (P < 0.01), total/high density lipoprotein cholesterol ratio (P < 0.01), free fatty acid levels (P < 0.04), systolic blood pressure (P < 0.04), microalbuminuria (P < 0.003), and intima-media thickness (P < 0.02). These results suggest that the Arg(972) IRS-1 variant could contribute to the risk for atherosclerotic cardiovascular diseases associated with type 2 diabetes by producing a cluster of insulin resistance-related metabolic abnormalities.

Marini, M.a., Frontoni, S., Mineo, D., Bracaglia, D., Cardellini, M., De Nicolais, P., et al. (2003). The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 88(7), 3368-3371 [10.1210/jc.2002-021716].

The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients

MARINI, MARIA ADELAIDE;FRONTONI, SIMONA;MINEO, DAVIDE;CARDELLINI, MARINA;D'ALFONSO, ROSSELLA;LAURO, DAVIDE;FEDERICI, MASSIMO;GAMBARDELLA, SERGIO;LAURO, RENATO;
2003-07-01

Abstract

The insulin receptor substrate-1 (IRS-1) gene has been considered a candidate for insulin resistance, type 2 diabetes, and coronary artery disease. To investigate the relationship between the common Gly(972)Arg IRS-1 variant and the presence of cardiovascular risk factors, 153 glucose-tolerant, unrelated offspring of type 2 diabetic patients were studied. There were no differences between Arg(972) IRS-1 carriers and noncarriers in age, gender, body mass index, waist/hip ratio, body composition, fasting glucose and insulin levels, and glucose or insulin levels during the oral glucose tolerance test. Insulin sensitivity, assessed by hyperinsulinemic-euglycemic clamp, was significantly reduced in carriers of Arg(972) IRS-1 (P < 0.03). Carriers of Arg(972) IRS-1 displayed many features of the insulin resistance syndrome, including higher values for serum triglycerides (P < 0.01), total/high density lipoprotein cholesterol ratio (P < 0.01), free fatty acid levels (P < 0.04), systolic blood pressure (P < 0.04), microalbuminuria (P < 0.003), and intima-media thickness (P < 0.02). These results suggest that the Arg(972) IRS-1 variant could contribute to the risk for atherosclerotic cardiovascular diseases associated with type 2 diabetes by producing a cluster of insulin resistance-related metabolic abnormalities.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/09 - Medicina Interna
Settore BIO/12
Settore MED/13 - Endocrinologia
Settore M-EDF/01 - Metodi e Didattiche delle Attivita' Motorie
Settore MED/49 - Scienze Tecniche Dietetiche Applicate
English
Con Impact Factor ISI
Male; Insulin Receptor Substrate Proteins; Middle Aged; Phosphoproteins; Female; Genetic Variation; Risk Factors; Diabetes Mellitus, Type 2; Humans; Parents; Point Mutation; Family Health; Adult; Genetic Predisposition to Disease
Marini, M.a., Frontoni, S., Mineo, D., Bracaglia, D., Cardellini, M., De Nicolais, P., et al. (2003). The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 88(7), 3368-3371 [10.1210/jc.2002-021716].
Marini, Ma; Frontoni, S; Mineo, D; Bracaglia, D; Cardellini, M; De Nicolais, P; Baroni, A; D'Alfonso, R; Perna, M; Lauro, D; Federici, M; Gambardella, S; Lauro, R; Sesti, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/35512
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 48
social impact